The Covid-19 pandemic has had a transformative effect on every aspect of the healthcare landscape, perhaps nowhere more so than in drug development as pharma companies have raced to develop viable treatment options.
Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company's work in HIV and hepatitis and how her personal background informed her team's work in developing a Covid-19 treatment.
No comments